PRC Clinical boosts gene therapy offerings

Lab work

San Bruno, CA-based PRC Clinical is expanding both its gene therapy and Parkinson's disease offering for an undisclosed Boston sponsor.

While not naming the company it’s working with, the Silicon Valley CRO said it is supporting the sponsor with “full clinical operations and site management for this multi-center study.”

PRC Clinical said it also helped move on from the study being an investigator-held IND over to the industry sponsor, as it seeks to boost its experience in this tough research and manufacturing field.

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

“This additional project strengthens our commitment to helping sponsors test and validate new, cutting-edge treatments" said Curtis Head, CEO at PRC Clinical.

“We're proud that regenerative medicine--including ophthalmology, oncology, neurology and other ageing associated diseases are within our core expertise.”

The company has a history of working in regenerative medicine and is already collaborating with the California Institute for Regenerative Medicine (CIRM) and is a member of the Alliance for Regenerative Medicine (ARM).

Big Pharma members of ARM include Pfizer ($PFE), Johnson & Johnson ($JNJ) and Novartis ($NVS).

There’s been nearly a dozen completed gene therapy trials over the past decade, however nearly all of them have not lived up to the heights first expected in terms of efficacy, but have helped build a better picture in terms of safety.

PRC, which has been around since 2003, has moved more deeply into regenerative medicine in recent years.

- check out the release

Related Article:
Sanofi embarks on an $845M gene therapy R&D odyssey with Voyager

Suggested Articles

Clinical trial firm Phesi’s new report is some grim reading for the life science industry: Studies for new drugs are still suffering.

Tempus fugit: And time especially flies when it comes clinical trials. Covance is teaming up with the suitably named Tempus to clip its wings.

PPD has raised its quarterly guidance after weathering the COVID-19 storm and is immediately making a secondary offering of 38 million shares.